Comparative Review of Standardized Incidence Ratio of Nonlymphoid, De Novo Malignancies After Liver Transplant Versus After Kidney Transplant

被引:0
作者
Kim, Andrew [1 ]
Waldron, Olivia [1 ]
Daoud, Deborah [2 ]
Huang, Yihe [3 ]
Patel, Jay [4 ]
Hong, Johnny [5 ]
Butler, Thomas [5 ]
Jain, Ashokkumar [5 ]
机构
[1] Penn State Univ, Coll Med, Hershey, PA USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Gen Surg, New Brunswick, NJ USA
[3] Biogen, Cambridge, MA USA
[4] VCU Med Ctr, Dept Cardiothorac Surg, Richmond, VA USA
[5] Penn State Hlth Milton S Hershey Med Ctr, Dept Surg, Div Transplant Surg, Hershey, PA USA
关键词
Cancer; Immunosuppression; Solid organ rejection; Surveillance; RENAL-TRANSPLANTATION; CANCER-RISK; RECIPIENTS; ORGAN; IMMUNOSUPPRESSION; TUMORS; OUTCOMES; THERAPY; HEART;
D O I
10.6002/ect.2024.0136
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: De novo malignancies are the most common cause of death after solid-organ transplant. Here, we aimed to summarize standard incidence ratios of de novo malignancies after liver and kidney transplant within the same geographical locations, compare these ratios among different types of de novo malignancies after liver and kidney transplant, and elucidate differences in de novo malignancies between liver and kidney transplant recipients. Materials and Methods: We performed a systematic review to identify studies on standard incidence ratios of de novo malignancies after liver and kidney transplant in the United Kingdom, Sweden, South Korea, and Taiwan. Results: Four articles reported standard incidence ratios of de novo malignancies in 14 016 liver transplant recipients (mean follow-up 4.3 +/- 0.7 y) and 48 179 kidney transplant recipients (mean follow-up 6.1 +/- 2.1 y). Mean ratios of oropharyngeal, pulmonary, colorectal, renal, and breast malignancies were 5.3, 1.6, 1.9, 1.8, and 1.1, respectively, after liver transplant and 3.2, 1.7, 1.5, 17.0, and 1.3, respectively, after kidney transplant. Mean ratios of bladder, cervix- uterus, and stomach de novo malignancies were 1.8, 2.0, and 2.9, respectively, after liver transplant and 13.0, 1.9, and 1.9, respectively, after kidney transplant. Mean ratios of prostatic and esophageal malignancies were 1.6 and 1.8 after liver transplant and 1.2 and 1.1 after kidney transplant. Mean ratio of ovarian cancer was 1.2 and 2.9, respectively, after liver and kidney transplant. Conclusions: Low-frequency and lower standard incidence ratios were observed for testicular, ovarian and central nervous system malignancies after kidney and liver transplant. Standard incidence ratios of oropharyngeal and hepatic malignancies were higher after liver transplant compared with kidney transplant. After kidney transplant, standardized ration for renal malignancy were 9.4 times and bladder malignancies were 7.2 times higher compared with liver transplant recipients.
引用
收藏
页码:600 / 606
页数:7
相关论文
共 50 条
  • [1] De Novo Malignancy After Liver Transplant
    Sanaei, Ahmad Khalid
    Aliakbarian, Mohsen
    Kazemi, Kourosh
    Nikeghbalian, Saman
    Shamsaeefar, Ali
    Mehdi, Syed Haider
    Bahreini, Amin
    Dehghani, Seyed Mohsen
    Geramizadeh, Bita
    Malekhosseini, Seyed Ali
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2015, 13 (02) : 163 - 166
  • [2] De Novo Malignancies After Liver Transplantation: A Single Institution Experience
    Egeli, Tufan
    Unek, Tarkan
    Ozbilgin, Mucahit
    Agalar, Cihan
    Derici, Serhan
    Akarsu, Mesut
    Unek, Ilkay Tugba
    Aysin, Murat
    Bacakoglu, Aylin
    Astarcioglu, Ibrahim
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 (01) : 74 - 78
  • [3] De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan
    Yeh, Chun-Chieh
    Khan, Arshad
    Muo, Chih-Hsin
    Yang, Horng-Ren
    Li, Ping-Chun
    Chang, Chao-Hsiang
    Chen, Ta-Liang
    Jeng, Long-Bin
    Liao, Chien-Chang
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2020, 18 (02) : 224 - 233
  • [4] Review of Standardized Incidence Ratios (SIR) of non-lymphoid de novo malignancies after liver transplantation: Structured analysis of global differences
    Patel, Jay A.
    Daoud, Deborah
    Jain, Ashokkumar
    TRANSPLANTATION REVIEWS, 2022, 36 (01)
  • [5] De novo inflammatory bowel disease after pediatric kidney or liver transplant
    Fernandes, Melissa A.
    Braun, Hillary J.
    Evason, Kim
    Rhee, Sue
    Perito, Emily R.
    PEDIATRIC TRANSPLANTATION, 2017, 21 (01)
  • [6] Recurrent Nonhepatic and De Novo Malignancies After Liver Transplantation
    Jain, Ashokkumar
    Fiaz, Omer
    Sheikh, Baber
    Sharma, Rajeev
    Safadjou, Saman
    Kashyap, Randeep
    Bryan, Leah
    Batzold, Pam
    Orloff, Mark
    TRANSPLANTATION, 2009, 88 (05) : 706 - 710
  • [7] A Comparative Review of Standardized Incidence Ratios of De Novo Malignancies Post Liver Transplantation in Males Versus Females
    Waldron, Olivia
    Kim, Andrew
    Daoud, Deborah
    Zhu, Junjia
    Patel, Jay
    Butler, Thomas
    Zhou, Shouhao
    Jain, Ashokkumar
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (06) : 1365 - 1373
  • [8] Management of de novo malignancies after liver transplantation
    Pillai, Anjana A.
    TRANSPLANTATION REVIEWS, 2015, 29 (01) : 38 - 41
  • [9] De Novo Malignancies after Kidney Transplantation
    Al-Adra, David
    Al-Qaoud, Talal
    Fowler, Kevin
    Wong, Germaine
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03): : 434 - 443
  • [10] Survival after the diagnosis of de novo malignancy in liver transplant recipients
    Taborelli, Martina
    Piselli, Pierluca
    Ettorre, Giuseppe Maria
    Baccarani, Umberto
    Burra, Patrizia
    Lauro, Augusto
    Galatioto, Laura
    Rendina, Maria
    Shalaby, Sarah
    Petrara, Raffaella
    Nudo, Francesco
    Toti, Luca
    Fantolall, Giovanni
    Cimaglia, Claudia
    Agresta, Alessandro
    Vennarecci, Giovanni
    Pinna, Antonio Daniele
    Gruttadauria, Salvatore
    Risaliti, Andrea
    Di Leo, Alfredo
    Rossi, Massimo
    Tisone, Giuseppe
    Zambonill, Fausto
    Serraino, Diego
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 232 - 239